Search
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Rupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria
Products: RUPATADINA DOC GENERICIPotassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigational[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient. … Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution.
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617] … [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.
Categories: Endothelin A Receptor AntagonistsEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders.
Products: ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 2 ADET, ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 20 ADETBicalutamide
go.drugbank.com/drugs/DB01128ApprovedInvestigationalIt is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: BICALUTAMID 1A PHARMA50MG, BICALUTAMID 1A PHARMA 50Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.